Multivariate models of prognostic features associated with decreased overall survival and progression-free survival
| Factor analyzed . | Overall survival P(RR) . | Progression-free survival P (RR) . |
|---|---|---|
| Age (≥ 40 y) | .03 (4.2) | .40 (1.5) |
| Stage of disease (stage III) | .01 (2.5) | .0002 (3.3) |
| Type of MM (IgA) | .03 (2.9) | .29 (1.6) |
| Female patient | .46 (0.8) | .45 (1.3) |
| Female donor | .90 (1.0) | .36 (0.7) |
| Interval from diagnosis to BMT (≥ 1 y) | .80 (0.9) | .74 (0.9) |
| Factor analyzed . | Overall survival P(RR) . | Progression-free survival P (RR) . |
|---|---|---|
| Age (≥ 40 y) | .03 (4.2) | .40 (1.5) |
| Stage of disease (stage III) | .01 (2.5) | .0002 (3.3) |
| Type of MM (IgA) | .03 (2.9) | .29 (1.6) |
| Female patient | .46 (0.8) | .45 (1.3) |
| Female donor | .90 (1.0) | .36 (0.7) |
| Interval from diagnosis to BMT (≥ 1 y) | .80 (0.9) | .74 (0.9) |
N = 62.
RR indicates relative risk; MM, multiple myeloma; IgA, immunoglobulin A; BMT, bone marrow transplantation.